Skip to content
easybpt
Browse topics

Pharmacology

JAK inhibitors: mechanism and safety

How JAK inhibitors block cytokine signalling through JAK-STAT, why receptor pairings predict their benefits and adverse effects, how their kinetics and clearance shape dosing, and what ORAL Surveillance changed about MACE, cancer and VTE risk.

Tier 2Medical sciences concept

Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made

3 questions9 flashcards

At a glance

  • Many cytokine receptors have no kinase of their own. They rely on associated Janus kinases (JAK1, JAK2, JAK3, TYK2) to phosphorylate STAT proteins, which dimerise and switch on genes in the nucleus.
  • JAK inhibitors are oral small molecules that compete for the ATP-binding site. One drug therefore damps many cytokines at once.
  • Which JAK pair a receptor uses predicts both benefit and harm. JAK2 block gives anaemia; JAK1/JAK3 block gives lymphopenia and zoster.

Loading the rest of the note…

Finished reading?

Test yourself on it:3 questions9 flashcards

Sources

Last updated
14 November 2026
What changed
  • 14 November 2026 Turnstile bot check on sign-in and signed-out feedback

Send feedback

Type of feedback

The page you're on and your device type are attached automatically.